About Xencor, Inc.
https://www.xencor.comXencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases.
CEO
Bassil I. Dahiyat
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 167
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
RBC Capital
Outperform
Wedbush
Outperform
Barclays
Overweight
Cantor Fitzgerald
Overweight
JP Morgan
Overweight
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:11.81M
Value:$170.61M
BLACKROCK INC.
Shares:11.1M
Value:$160.44M
PRIMECAP MANAGEMENT CO/CA/
Shares:10.68M
Value:$154.25M
Summary
Showing Top 3 of 259
About Xencor, Inc.
https://www.xencor.comXencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $21M ▼ | $68.52M ▼ | $-6.03M ▲ | -28.7% ▲ | $-0.08 ▲ | $4.23M ▲ |
| Q2-2025 | $43.61M ▲ | $74.13M ▲ | $-30.82M ▲ | -70.69% ▲ | $-0.41 ▲ | $-20.18M ▲ |
| Q1-2025 | $32.73M ▼ | $73.22M ▲ | $-48.42M ▲ | -147.92% ▼ | $-0.66 ▲ | $-36.91M ▼ |
| Q4-2024 | $70.02M ▲ | $65.97M ▼ | $-53.48M ▼ | -76.38% ▲ | $-0.73 ▼ | $-15.71M ▲ |
| Q3-2024 | $17.8M | $72.99M | $-46.29M | -260.1% | $-0.71 | $-35.36M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $471.04M ▲ | $868.81M ▼ | $243.5M ▼ | $625.32M ▲ |
| Q2-2025 | $443.86M ▼ | $879.42M ▼ | $259.07M ▼ | $620.35M ▼ |
| Q1-2025 | $469.57M ▼ | $904.69M ▼ | $264.81M ▼ | $639.87M ▼ |
| Q4-2024 | $497.77M ▼ | $951.95M ▼ | $277.92M ▲ | $677.61M ▼ |
| Q3-2024 | $542.98M | $983.63M | $262.74M | $723.84M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-6.03M ▲ | $-30.82M ▲ | $14.67M ▼ | $0 ▼ | $-16.15M ▼ | $-31M ▲ |
| Q2-2025 | $-30.82M ▲ | $-36.37M ▼ | $40.48M ▲ | $662K ▼ | $4.77M ▲ | $-36.75M ▼ |
| Q1-2025 | $-48.42M ▲ | $-16.22M ▲ | $11.94M ▼ | $2.97M ▼ | $-1.2M ▼ | $-17.66M ▲ |
| Q4-2024 | $-54.13M ▼ | $-55.58M ▼ | $57.25M ▲ | $10.17M ▼ | $11.85M ▲ | $-58.26M ▼ |
| Q3-2024 | $-48.42M | $-26.02M | $-163.46M | $187.74M | $-1.74M | $-28.14M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Milestone | $30.00M ▲ | $0 ▼ | $10.00M ▲ | $30.00M ▲ |
 Royalty | $0 ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
CEO
Bassil I. Dahiyat
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 167
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
RBC Capital
Outperform
Wedbush
Outperform
Barclays
Overweight
Cantor Fitzgerald
Overweight
JP Morgan
Overweight
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:11.81M
Value:$170.61M
BLACKROCK INC.
Shares:11.1M
Value:$160.44M
PRIMECAP MANAGEMENT CO/CA/
Shares:10.68M
Value:$154.25M
Summary
Showing Top 3 of 259